Retatrutide Cuts Knee Pain In Two Large Trials
Across TRIUMPH-4 and TRIUMPH-1-OA, about two-thirds of patients on retatrutide at least halved their knee pain, against 38 percent on placebo. The drug isn't approved yet, and the replacement question stays open.
Knee pain tracks the load on the joint, and a drug that takes off a quarter of a patient's weight moves the load itself.
Retatrutide cut knee pain scores nearly twice as much as placebo in two phase 3 trials published November 8. The New England Journal of Medicine paper covers TRIUMPH-4 and TRIUMPH-1-OA, two Eli Lilly-funded trials in adults with painful knee osteoarthritis and a body mass index of 27 or higher, none of them with diabetes.
TRIUMPH-4 enrolled 445 people on 9 or 12 milligrams weekly and read out at week 68. Pain on the WOMAC index fell 3.96 points on 9 milligrams and 3.74 on 12, against 2.12 on placebo, differences of 1.83 and 1.61 points with P below 0.001. Weight fell 20.0 percent and 23.7 percent against 4.6 percent on placebo.
TRIUMPH-1-OA enrolled 574 people on 4, 9 or 12 milligrams and read out at week 80. Pooled across the trials, 63 to 70 percent of patients on retatrutide cut their pain at least in half, against 38 percent on placebo, and about 64 to 65 percent at least halved their function limits against 33 percent.
The drug works three hormone receptors at once, GIP, GLP-1 and glucagon, where semaglutide works one and tirzepatide works two. Current drugs typically take off 10 to 20 percent of body weight, and retatrutide's trials printed 20 to 25 percent. Lead author Thomas Schnitzer of Northwestern credits the mechanics, in his words, "you're loading your knees less and therefore, there's less pain."
The limits are plain in the paper. Gut side effects were the most common problem, and 4 to 8 percent of patients stopped treatment over side effects depending on dose. The trials excluded people who need a knee replacement, so the biggest question stays open: nobody knows yet whether the drug slows the disease enough to cut replacements, or whether it helps patients who aren't overweight. Retatrutide isn't FDA-approved.
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.